ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 193 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2020. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,854,754 | -20.8% | 107,765 | +2.3% | 0.01% | -26.7% |
| Q2 2023 | $4,867,197 | +24.1% | 105,305 | +7.7% | 0.02% | +15.4% |
| Q1 2023 | $3,922,462 | -12.5% | 97,817 | +1.1% | 0.01% | -13.3% |
| Q4 2022 | $4,483,354 | +22.8% | 96,770 | +7.5% | 0.02% | +15.4% |
| Q3 2022 | $3,652,000 | -27.4% | 90,055 | +7.9% | 0.01% | -27.8% |
| Q2 2022 | $5,027,000 | -17.2% | 83,443 | -0.2% | 0.02% | +5.9% |
| Q1 2022 | $6,072,000 | -5.9% | 83,607 | +9.0% | 0.02% | +13.3% |
| Q4 2021 | $6,450,000 | -2.6% | 76,709 | +4.5% | 0.02% | 0.0% |
| Q3 2021 | $6,621,000 | -4.8% | 73,412 | +0.7% | 0.02% | -16.7% |
| Q2 2021 | $6,952,000 | -12.9% | 72,906 | +4.1% | 0.02% | -18.2% |
| Q1 2021 | $7,978,000 | -19.6% | 70,065 | -2.3% | 0.02% | -18.5% |
| Q4 2020 | $9,929,000 | +78.2% | 71,729 | +5.8% | 0.03% | +35.0% |
| Q3 2020 | $5,573,000 | +12.0% | 67,812 | +6.5% | 0.02% | +5.3% |
| Q2 2020 | $4,978,000 | +81.9% | 63,646 | +3.4% | 0.02% | +26.7% |
| Q1 2020 | $2,736,000 | – | 61,571 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |